Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma

Executive Summary

The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.

Advertisement

Related Content

Will Recent Excessive Pricing Cases Lay Down Precedent For Future?
Will Recent Excessive Pricing Cases Lay Down Precedent For Future?
Pharma Cases Show How Brexit Could Hit Alignment Of UK & EU Competition Law
ABPI Welcomes Amended Legislation On Curbing Excessive Unbranded Drug Prices
Actavis UK’s ‘Excessive’ Price Hikes Targeted In Latest Competition Inquiry
UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel